Meningococcal Disease: Recommended vaccinations
Back to search
Export to spreadsheet
  General recommendation
  Recommendation for specific groups only
  Catch-up (e.g. if previous doses missed)
 		 Vaccination not funded by the National Health system
 		 Mandatory vaccination
WeeksMonthsYears
62345610111213141521011121314151618192429≥ 30
Austria
MenB1
MenB
MCV4/MenB
MCV4
Belgium
MCV4
MCV42
Bulgaria
Croatia
MCV4/MenB3
Cyprus
MCV4
MPSV44
Czechia
MenB5
MenB5
MCV4/MenB5
MCV4/MenB5
MCV4/MenB5
Denmark
Estonia
Finland
MCV46
MCV4/MenB7
MCV4/MenB8
MenB9
MCV410
France
MenB11
MenB
MCV412
MCV4/MenB
MCV413
MCV4/MenB
Germany
MenB14
MenB14
MenB14
MCV414
MCV414
Greece
MenB
MenB
MenC15
MenB
MCV4
MCV4
MCV4/MenB
Hungary
MenC
MenC
MenC16
Iceland
MCV4
Ireland
MenB
MenB
MenB
MenC
MCV4
Italy
MenB17
MenB17
MCV4
MenB17
MenB17
MCV418
Latvia
Liechtenstein
MCV419
MCV420
Lithuania
MenB
MenB
MenB21
Luxembourg
MenB
MenB
MenB
MCV4
MCV4
Malta
MenB
MCV4
MenB
MenB
MCV4
MCV4
Netherlands
MCV422
MCV422
Norway
Poland
MenC
MenC
Portugal
MenB
MenB
MCV4/MenB
Romania
Slovakia
MCV423
MenB23
Slovenia
Spain
MenB24
MenB - MenC24
MenB - MenC24
MCV425
MCV426
Sweden

Footnotes:

  1. MenB vaccination is recommended as early as possible from the age of 2 months and not funded. Catch-up vaccinations are recommended up to the age of 25. MenACWY vaccination is recommended as early as possible at the age of 13 months and not funded. One dose of the tetravalent conjugated meningococcal vaccine is recommended between the ages of 10-13 and funded. Additionally, please refer to official recommendations for timing and number of doses required according to age: https://www.sozialministerium.gv.at/impfplan (p. 77ff)
  2. Adolescent dose recommended but not implemented in free vaccination programs
  3. Vaccination is recommended and funded by Croatian Health Insurance for certain at risk groups, both MenB and MenACWY (children and adults - for example: splenectomized individuals, people after HSCTs, persons with disorders of complement components, including those receiving eculizumab or ravulizumab therapy)
  4. vaccines only given on specific indications
  5. MenB vaccination for infants is covered by health insurance if the schedule is started before the age of 1 year, and vaccination for adolescents if vaccination is started at the age interval from 14 to 16 years. MCV4 vaccination for toodlers is covered by health insurance if is administered at the age interval from 12 to 23 months and vaccination for adolescents if vaccination is started at the age interval from 14 to 16 years. Vaccination with MenB and MCV4 vaccines is covered by health insurance for persons of all ages with immune disorders. More details of the recommendation is available at: https://www.vakcinace.eu/doporuceni-a-stanoviska/doporuceni-ceske-vakcinologicke-spolecnosti-cls-jep-pro-ockovani-proti-invazivnim-meningokokovym-2
  6. MCV4: The vaccination series includes a total of two doses, with the second doses been administered at least two months after the first dose. In addition, one booster dose will be given at twelve months of age, no earlier than two months after the second dose of Nimenrix. Nimenrix is administered to children aged six weeks to under two years, while Menveo is recommended for individuals aged two years and older. The number of doses and administration schedule vary depending on the recipient's age. For detailed guidance, please refer to the official information available at: https://thl.fi/aiheet/infektiotaudit-ja-rokotukset/rokotteet-a-o/meningokokkirokotteet/meningokokki-acwy-rokote
  7. MCV4: The vaccination series includes a total of two doses, with the second doses been administered at least two months after the first dose. In addition, one booster dose will be given at twelve months of age, no earlier than two months after the second dose of Nimenrix. Nimenrix is administered to children aged six weeks to under two years, while Menveo is recommended for individuals aged two years and older. The number of doses and administration schedule vary depending on the recipient's age. For detailed guidance, please refer to the official information available at: https://thl.fi/aiheet/infektiotaudit-ja-rokotukset/rokotteet-a-o/meningokokkirokotteet/meningokokki-acwy-rokote MenB: Bexsero vaccine is administered to infants aged 2 to 5 months as a series of three doses, spaced at least one month apart. A booster dose is then recommended at 12 to 15 months of age, provided that at least six months have passed since the last dose. The number of doses and administration schedule vary depending on the recipient's age. For detailed guidance, please refer to the official information available at: https://thl.fi/aiheet/infektiotaudit-ja-rokotukset/rokotteet-a-o/meningokokkirokotteet/meningokokki-b-rokote
  8. Booster doses are administered only under specific circumstances, based on the age at which previous doses were received. Additional information available at: https://thl.fi/aiheet/infektiotaudit-ja-rokotukset/rokotteet-a-o/meningokokkirokotteet/meningokokki-acwy-rokote AND https://thl.fi/aiheet/infektiotaudit-ja-rokotukset/rokotteet-a-o/meningokokkirokotteet/meningokokki-b-rokote
  9. Booster doses are administered only under specific circumstances, based on the age at which previous doses were received. Additional information available at: https://thl.fi/aiheet/infektiotaudit-ja-rokotukset/rokotteet-a-o/meningokokkirokotteet/meningokokki-acwy-rokote AND https://thl.fi/aiheet/infektiotaudit-ja-rokotukset/rokotteet-a-o/meningokokkirokotteet/meningokokki-b-rokote
  10. A MCV4 dose is administered to military conscripts upon commencement of their service (compulsory for men and voluntary for women). While the majority begin service between the ages of 19 and 20, the official age range for enlistment spans from 18 to 29 years.
  11. Vaccination introduced in 2022. Mandatory since January 2025.
  12. Introduced in January 2025 in replacement of monovalent MenC
  13. More information available at: https://www.service-public.fr/particuliers/actualites/A16520
  14. For MenB, according to the product information, the vaccination series consists of 3 vaccine doses for children aged 2–23 months and 2 vaccine doses for children aged 24 months and older. For MenACWY, recommendation in October 2025 to vaccinate at age 12-14 (up until age 24) and recommendation against MenC vaccination for infants and small children
  15. MenC: 1 dose at the age of 10 months
  16. Since January 1st, 2017, the meningococcal C vaccine is offered to all children aged under 2 years with 100% reimbursement on a voluntary-based approach.
  17. Please refer to local recommendations for age of administration. MenB should not to be co-administered with other vaccinations.
  18. Meningococcal ACWY, one dose for adolescents age 12-18
  19. Not part of the routine vaccination programme but can be offered by health professionals. Catch-up possible until 5 years of age.
  20. Not part of the routine vaccination programme but can be offered by health professionals. Catch-up possible until 20 years of age.
  21. Can be administered concomitantly with MMR
  22. Also prescribed to medical high risk groups of other ages by the attending medical doctor and reimbursed by the health insurer (https://lci.rivm.nl/factsheets/meningokokken-acwy-vaccinatie)
  23. Generally recommended to children with no legislative support.
  24. Additional information available at https://www.sanidad.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/comoTrabajamos/enf-meningococica.htm
  25. One dose at 12 years to individuals who have not received any doses of MCV4 since 10 years of age. Additional information available at https://www.sanidad.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/comoTrabajamos/enf-meningococica.htm
  26. The catch-up vaccination programme for individuals aged 13 to 18 years will be introduced gradually (more information available at: https://www.sanidad.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/programasDeVacunacion/adolescentes-meningo/home.htm